Compound ID | 1190
Class: FtsZ inhibitor
| Spectrum of activity: | Gram-positive |
| Details of activity: | Inhibits the Filamentous Temperature Sensitive mutant Z (FtsZ), a cytoplasmic essential protein in the cell division process. |
| Description: | Synthetic compound; methoxybenzamide; oral administration |
| Institute where first reported: | TAXIS Pharmaceuticals |
| Year first mentioned: | 2015 |
| Highest developmental phase: | Phase 1 |
| Development status: | Active |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| Guide to Pharmacology: | TXA709 |
| Citations: |
|